$IKT News
Last published 1d ago
- 1d agoIKTInhibikase Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoIKTInhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent ActivityGlobeNewswireWILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended September 30, 2026, and highlighted recent developments.
- 2w agoIKTInhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026GlobeNewswireWILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel
- 3w agoIKTInhibikase Therapeutics Appoints Scott Wasserman to Board of DirectorsGlobeNewswireWILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel
- 3mo agoIKTInhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent ActivityGlobeNewswireWILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel
- 3mo agoIKTInhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAHGlobeNewswireWILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary
- 4mo agoIKTInhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) FacilityGlobeNewswireWILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary
- 4mo agoIKTInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), today announced that the Company granted non-qualified stock options to
- 6mo agoIKTInhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent ActivityGlobeNewswireWILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension
- 7mo agoIKTInhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial HypertensionGlobeNewswireWILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial
- 7mo agoIKTInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), today announced that the Company granted non-qualified stock options to purchase up to an
- 7mo agoIKTInhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent ActivityGlobeNewswireWILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of
- 11mo agoIKTInhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireWILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of
- 11mo agoIKTInhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireBOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of
- 11mo agoIKTInhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial HypertensionGlobeNewswirePhase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase
- 12mo agoIKTInhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent ActivityGlobeNewswireBOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of
- 1y agoIKTInhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy OfficerGlobeNewswireBOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of
- 1y agoIKTInhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent ActivityGlobeNewswireBOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of
- 1y agoIKTInhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent ActivityGlobeNewswireBOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor
- 1y agoIKTInhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial OfficerGlobeNewswireBOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor
- 1y agoIKTInhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent ActivityGlobeNewswireBOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to
- 1y agoIKTInhibikase Announces Expansion of Senior Leadership TeamGlobeNewswire--- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of Directors ---
- 1y agoIKTInhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's GrowthGlobeNewswire-- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb. 18, 2025
- 1y agoIKTInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent ActivityGlobeNewswire-- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension -- --201
- 2y agoIKTInhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial HypertensionGlobeNewswire-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 -- BOSTON and
- 2y agoIKTInhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial HypertensionGlobeNewswire-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc.
- 2y agoIKTInhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoIKTInhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period ActivityGlobeNewswireBOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024GlobeNewswireBOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics Completes Enrollment of the Phase 2 '201' Trial Evaluating Risvodetinib in Untreated Parkinson's DiseaseGlobeNewswireBOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development ProgramsGlobeNewswire- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or
- 2y agoIKTInhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionGlobeNewswireBOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoIKTInhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityGlobeNewswireBOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementGlobeNewswireBOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial HypertensionGlobeNewswire- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension – BOSTON and ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase
- 2y agoIKTInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsGlobeNewswireBOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionGlobeNewswireBOSTON and ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoIKTInhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ActivityGlobeNewswireBOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersGlobeNewswireBOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001ProGlobeNewswireBOSTON and ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal CancersGlobeNewswireBOSTON and ATLANTA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with RisvodetinibGlobeNewswireData demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volunteers or worsening of symptoms in participants taking anti-PD medications BOSTON and
- 2y agoIKTInhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph FrattaroliGlobeNewswireBOSTON and ATLANTA, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsGlobeNewswireBOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 2y agoIKTInhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001ProGlobeNewswire- Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications - - Bioequivalence to 400 mg and 600 mg imatinib mesylate completed with
- 2y agoIKTInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period ActivityGlobeNewswireBOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
- 3y agoIKTCorrecting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023GlobeNewswireThis release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, "second quarter" rather than
- 3y agoIKTInhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023GlobeNewswireBOSTON and ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to